Errors in Key Points, Abstract, Results, and Discussion

00:00 - 17 Feb 2026

In the Original Investigation titled “Subsequent Meningiomas Among Survivors of Childhood Cancer,” published December 11, 2025, there were errors in the Key Points, Abstract, Results, and Discussion, in which it was incorrectly reported that 6-mercaptopurine (6-MP) was the antimetabolite exposure. However, in all analyses, the antimetabolite exposure was actually modeled as a composite class variable that included methotrexate, 6-MP, 6-thioguanine, and cytarabin. The language throughout the article has been updated to antimetabolite chemotherapy. The authors have explained the error in a Comment.2 This article has been corrected.